Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

5,405 recalls, newest first

Class II · Moderate risk

Latanoprost 0.025% eye drop

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-650-2013
Class II · Moderate risk

Laser ophthalmic drops

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-649-2013
Class II · Moderate risk

Itraconazole 1% eye ointment

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-648-2013
Class II · Moderate risk

Injection vehicle

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-647-2013
Class II · Moderate risk

Hydroxyprogesterone 250 mg/ml

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-646-2013
Class II · Moderate risk

HCG 500 units/ml

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-645-2013
Class II · Moderate risk

HCG 2000 units/ml

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-644-2013
Class II · Moderate risk

HCG 1000 units/ml

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-643-2013
Class II · Moderate risk

Estradiol Valerate 30 mg/ml

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-641-2013
Class II · Moderate risk

Estradiol Valerate 20 mg/ml

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-640-2013
Class II · Moderate risk

Estradiol Cypionate 5 mg/ml

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-639-2013
Class II · Moderate risk

Diazepam 5 mg/ml

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-638-2013
Class II · Moderate risk

Cyclosporine 2% ophthalmic

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-637-2013
Class II · Moderate risk

Cataract drops

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-635-2013
Class II · Moderate risk

Acetylcysteine 2 % Solution

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-634-2013
Class II · Moderate risk

Acetylcysteine 20 % solution

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes.

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-633-2013
Class II · Moderate risk

Acetylcysteine 10 % Solution

Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-632-2013
Class II · Moderate risk

Avastin

Lack of Assurance of Sterility; product linked to adverse event reports of endophthalimitis eye infections and FDA inspection findings resulted in concerns regarding quality control processes

Terminated Sterility / contamination Clinical Specialties Compounding Pharmacy D-918-2013
Class II · Moderate risk

0.9% Sodium Chloride Injection

Lack of Assurance of Sterility: The product is being recall due to the product lot being incorrectly released without meeting product specifications. There is the potential for the solution to leak from the administrative port to the fill tube seal.

Terminated Sterility / contamination Hospira Inc. NDC 0409-7984-36 D-243-2013

Recalls by year